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Background and Aims: Atherosclerosis and osteoporosis share common risk factors,
as well as inflammatory mechanisms. Our aim was to understand how atherosclerotic
lesions are related with disturbances in bone.
Methods: Gene expression of pro-inflammatory and bone metabolism related proteins
(IL-1β, IL-6, IL-17A, TNF, RANKL, OPG, COL1, CTSK, OCL, TRAP, CBFA1, DKK1,
SOST, ADIPOQ, and ADIPOR1) were analyzed in arteries and bones from 45 deceased
donors and adipose tissue was used as control. Additionally, in 139 patients with
advanced atherosclerosis submitted to carotid endarterectomy we compared calcium
content (Alizarin red) and plaque inflammatory scores (CD3+, CD68+, and adiponectin) of
patients with normal bone mineral density (BMD) with those with low BMD and explored
the associations between gene expression in atherosclerotic plaques and BMD. Serum
levels of pro-inflammatory and bone related proteins were measured both in donors and
patients. Associations were investigated by the Pearson or Spearman correlation tests,
and multivariate regression analyzes were performed when justified.
Results: Gene expression of bone remodeling and pro-inflammatory proteins correlated
positively in bone and aorta, independently of age and sex of donors, but not in
adipose tissue. The expression of bone formation genes was significantly higher in
atheroma plaques from endarterectomized patients with normal vs. low BMD as well
as inflammatory CD68+ scores, regardless of patients’ age and sex, but not of body
mass index. No relationship was observed between serum levels and gene expression
levels of pro-inflammatory or bone remodeling proteins.
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Conclusions: Our results suggest that the relationship between bones and vessels
in the context of atherosclerotic disease and osteoporosis may rely on the intrinsic
connection between the tissues involved, independently of disease stage. Serum
measurements of pro-inflammatory and bone-remodeling proteins do not accurately
translate tissue pathologic processes.
Keywords: atherosclerosis, osteoporosis, pro inflammatory cytokines, bone remodeling biomarkers, tissue
expression analysis
INTRODUCTION
Atherosclerosis and osteoporosis are among the most prevalent
diseases, frequently occurring in the same individual, and their
prevalence increases with aging (1, 2).
Atherosclerosis is a chronic inflammatory process that evolves
from fatty streaks to atheroma plaques and causes progressive
stenosis of large and medium-sized arteries (3), as a consequence
of accumulation of lipids, inflammatory cells, fibrous elements,
cellular waste products and calcium (1).
Inflammation, as a key mechanism of atherosclerosis (2),
affects its progression throughout all phases (4). Endothelial
dysfunction and inflammatory lesions are mediated by several
pro-inflammatory cytokines, present in atherosclerotic plaques
produced by monocytes and macrophages (5). Infiltrates of
CD68-positive macrophages and CD3- and CD8-positive T cells
have been associated with plaque ruptures (6). Moreover, high
serum levels of interleukin (IL)-1β, IL-6 and tumor necrosis
factor (TNF) (3) are associated with an increase of cardiovascular
(CV) risk, as demonstrated by epidemiological studies (7).
Osteoporosis (OP) is a skeletal bone disorder characterized by
a decline in bone mineral density (BMD) and microarchitectural
deterioration of bone tissue, which causes a reduction in
bone strength and, consequently, leads to an increased risk
of fracture (8–10). BMD can be determined by dual x-ray
absorptiometry (DXA).
Bone is an active tissue, which is self-remodeled in a coupled
action of bone-resorbing cells, osteoclasts, and bone forming
cells, osteoblasts (11).
The Receptor Activator of NF-kB (RANK)/RANK Ligand
(RANKL)/Osteoprotegerin (OPG) system, essential to the
regulation of bone remodeling and to the physiopathology of OP
(12), is closely related to inflammation. Not only inflammatory
cells produce RANKL, but the interaction between RANK and
RANKL leads to the release of pro-inflammatory cytokines,
such as IL-1β, IL-6, and TNF, which increase bone resorption
(13). Interestingly, the RANK/RANKL/OPG system and the
Wnt pathway have also been implicated in the development
of atherosclerosis and could be contributing pathways in the
regulation of vascular calcification mechanisms (14).
These two diseases share common risk factors (1), as
well as molecular and pathophysiological mechanisms (13),
although conceivable common underlying mechanisms are not
yet fully understood.
Our aim was to understand the relationship between
atherosclerotic lesions and bone disturbances. Using samples
from deceased donors, we aimed to analyze if a link between
bone and vessel exists regarding gene expression patterns of
pro-inflammatory cytokines and bone remodeling markers.
Additionally, in a group of patients with advanced atherosclerosis
submitted to carotid endarterectomy, we aimed to understand
whether gene expression patterns of pro-inflammatory cytokines
and bone remodeling markers in atherosclerotic plaques and




A sample of bone from the iliac crest and a section of the
abdominal aorta were collected from 45 deceased donors at
the time of organ collection for transplantation, immediately
preserved at 4◦C and processed on average in <24 h. A
blood sample was also obtained. From a subgroup of seven
patients (four men and three women), an additional sample of
subcutaneous adipose tissue was collected. Due to confidentiality
aspects, no clinical information beyond age and gender could be
retrieved, but all of them had clearance to be organ donors, which




Atherosclerotic plaques and fasting blood samples were collected
from 139 patients submitted to carotid endarterectomy surgery.
A structured protocol was applied to all patients for recording
demographic data, CV risk factors, history of previous fractures,
personal and family history of OP, other comorbidities, lifestyle,
and past and current medication.
All patients performed a dual X-ray absorptiometry (DXA)
and were classified with osteoporosis, osteopenia or normal BMD
according to the WHO classification criteria (15).
This study was approved by the Ethics Committee of Centro
Académico de Medicina de Lisboa and patients signed written
informed consent prior to any protocol-specific procedure. All
proceedings were conducted in accordance with the regulations
governing biomedical investigation such as the Declaration of
Helsinki, as amended in Fortaleza, Brazil (2013) (16).
Biologic Samples Collection and Storage
Endarterectomy samples–the central and visually more
developed plaque was sectioned crosswise over the longitudinal
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axis in two sections: one for RNA extraction that was fragmented
in smaller pieces and immediately frozen in liquid nitrogen
(snap-frozen) and stored at −80◦C, and the other for histology
and immunohistochemistry that was frozen in optimal cutting
temperature compound (OCT) and stored at−80◦C.
Deceased organ donor samples—Bone biopsies and aorta
sections were processed the same way as the atheroma plaques.
Blood samples–were centrifuged upon arrival to the lab and
the serum was collected and stored at−80◦C for later analysis.
RNA Isolation From Bones and Aortas
Samples were reduced to a fine powder with a pestle and
mortar cold with liquid nitrogen and the RNA was extracted
with TRIzol R© (InvitrogenTM), according to a modified version
of Hughes et al. protocol (17). Briefly, the powder was placed
in TRIzol R© and homogenized, and chloroform was added to
solubilize the lipids. A digestion with proteinase Kwas performed
at 55◦C, and it was subsequently treated with isopropyl alcohol
to precipitate the RNA. The RNA pellet was cleaned with ethanol
and then dissolved in RNase/DNase-free water.
The RNA quantification and quality were obtained
by absorbance measured using the NanoDrop R© ND-
1000 Spectrophotometer (NanoDrop Technologies, Inc.,
Wilmington, USA).
RNA Expression–Quantitative RT-PCR
Total RNA was reverse-transcribed to cDNA according to the
manufacturer’s instructions (DyNAmo cDNA Synthesis Kit,
Thermo Fisher Scientific Inc., Waltham, MA, USA).
The quantitative PCR was performed using DyNAmo Flash
SYBR R© Green qPCR Kit (Thermo Fisher Scientific Inc.,
Waltham, MA, USA) and the results measured with Rotor
Gene 6000 (Qiagen, Germany) for deceased donors’ samples and
with 7500 Fast Real-Time PCR System (Applied Biosystems R©,
Foster City, CA, USA) for advanced atherosclerosis patients’
samples. The sequences of the primers used (IL-1β, IL-6, IL-
17A, TNF, RANKL, OPG, Collagen type I (COL1), Cathepsin K
(CTSK), Osteocalcin (OCL), Tartrate resistant acid phosphatase
(TRAP), Core-Binding Factor Alpha I (CBFA1), Dickkopf-
related protein 1 (DKK1), Sclerostin (SOST), Adiponectin
(ADIPOQ), Adiponectin receptor 1 (ADIPOR1) are listed in
Supplementary Tables 1, 2. The efficiency of qPCR was analyzed
using the standard curve method, as described previously (18).
The values obtainedwere normalized with the housekeeping gene
18S rRNA.
Histological Evaluation
Frozen plaques were sectioned crosswise over their longitudinal
axis using a cryostat, and the major segment was used for
histological analysis.
Alizarin Red S (Sigma, Missouri, USA) histological staining
was used for calcium determination. The protocol was adapted
(no de-paraffinization needed, slides were slowly immersed in
distilled water) from IHCWorld website (19).
Immunohistochemical staining of the plaques to identify
a proinflammatory/unstable profile was also performed with
CD3 (eBioscience, San Diego, USA), CD68 (eBioscience, San
Diego, USA) and Adiponectin (Boster Biological Technology,
Pleasanton, USA) antibodies. Tissue sections were incubated
with the primary antibody and with EnVision+ (Dako,
Glostrup, Denmark). Color was developed in solution
containing diaminobenzidine-tetrahydrochloride (Sigma,
Missouri, USA), 0.5% H2O2 in phosphate-buffered saline buffer
(pH 7.6). Slides were counterstained with hematoxylin and
mounted (20).
Histological and immunohistochemical evaluations were
performed using a semi-quantitative score of 0 to 3 (0–0 to 10%
staining; 1–10 to 50% staining; 2–50 to 75% staining; 3–more
than 75% staining). Slides were observed in a ZEISS Primo Star
(ZEISS, Oberkochen, Germany) microscope.
Serum Cytokine and Bone Markers
Quantification
RANKL andOPG serum levels were determined using Biomedica
ELISA (Enzyme-Linked Immunosorbent Assay) (Cat. No. BI-
20462 and BI-20403, respectively), and C-terminal telopeptide
of type 1 collagen (CTX) and procollagen type 1N propeptide
(P1NP) with SunRed Biological Technology (Cat. No. 201-12-
1350 and 201-12-2130, respectively). Data were acquired in the
microplate reader Infinite R© M200 (Tecan).
Cytometric Bead Array (CBA) determination was performed
for pro-inflammatory cytokines, IL-1β, IL-6, IL-17A, and TNF
[BDTM CBA Enhanced Sensitivity Flex Set; Cat. No. 561509 (for
IL-1β), Cat. No. 561512 (for IL-6), Cat. No. 562143 (for IL-17A),
and Cat. No. 561516 (for TNF)] and data were collected in the
AccuriTM C6 flow cytometer from BDTM Biosciences.
Statistical Analysis
Statistical analysis was performed using IBM SPSS version
20. Quantitative variables are described as means and
standard deviation and qualitative variables as percentages
and absolute frequencies.
Statistical significance was considered for a two-tailed
p < 0.05 and the confidence interval for all statistical
analyses was 95%. The normality of the distribution for
continuous variables was evaluated using Kolmogorov–Smirnov
test. Comparisons between groups and correlations were
performed using parametric and non-parametric tests, as
appropriate. When justified, multivariable linear regression




A total of 45 donors were included in this study with ages
ranging between 15 and 80 years old: 23 men with 49.6 ± 17.8
years old and 22 women with 61.1 ± 12.9 years old. The aortas
were evaluated macroscopically and in five of them (11.1%)
calcifications were visible. These patients corresponded to a 78-
year-old man and four women with a mean age of 66.5 ± 9.9
years old.
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FIGURE 1 | Correlations of gene expression levels between bone and aorta samples. IL, Interleukin; TNF, Tumor necrosis factor; RANKL, Receptor Activator of NF-kB
Ligand; OPG, Osteoprotegerin; COL1A1, Collagen type I; CTSK, Cathepsin K; OCL, Osteocalcin; TRAP, Tartrate resistant acid phosphatase; CBFA1, Core-Binding
Factor Alpha I; DKK1, Dickkopf-related protein 1; SOST, Sclerostin; AdipoQ, Adiponectin; AdipoR1, Adiponectin receptor 1.
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RNA Expression–Quantitative RT-PCR
A positive correlation between gene expression levels in bone and
aorta samples was observed for all studied genes, except OCL
gene (see Figure 1). The correlations found were classified, as
described by Evans (21), as weak for the TNF gene; moderate for
the IL-1β, IL-6, RANKL, COL1A1, CTSK, TRAP, ADIPOQ, and
ADIPOR1 genes; and strong for the IL-17A, OPG, CBFA1, DKK1,
and SOST genes.
No association was found between gene expression levels of
bone and aorta samples individually with adipose tissues samples.
Donors with macroscopic aortic calcifications had higher
expression of RANKL and TRAP in the aorta and of IL-17A and
SOST in bone—Supplementary Table 3.
No significant differences in the gene expression of
inflammatory and bone remodeling markers in aorta, bone
or adipose tissue samples were found between men and
women—Supplementary Table 4 neither in association with age.
Serum Cytokines and Bone Markers Analysis
We found that IL-1β levels were significantly higher in men than
in women [442.7 fg/mL (range 179.3–4569) vs. 89.4 fg/mL (range
38.9–504.9); p= 0.011]. Age did not influence serum cytokine or
bone markers levels.
No significant correlations were found between serum levels
and gene expression levels, either from bone, aorta or adipose
tissue samples, for any of the proteins studied.
Atherosclerosis Patients
Population Description
A total of 139 patients with advanced atherosclerosis were
included in the study, where 95 (68.3%) were men, 70.3 ± 8.7
years old, and 44 (31.7%) were women, 71.5± 9.6 years old.
We have further compared the clinical characteristics, co-
morbidities and therapies between patients with normal BMD
(t-score>−1) and patients with low BMD (t-score≤−1). Details
are listed in Table 1. Patients with low BMD were older (p =
0.001) and had lower BMI levels (p < 0.001). They did not differ
significantly in any of the other variables evaluated.
RNA Expression–Quantitative RT-PCR
Regarding bone remodeling markers in the atheroma plaques,
we found that genes associated with bone formation were
expressed at higher levels in patients with normal BMD than in
patients with low BMD (Table 2). The difference was statistically
significant for, specifically, CBFA1 (0.98 ± 0.08 vs. 0.71 ± 0.06,
p = 0.009) and OCL (1.27 ± 0.12 vs. 0.83 ± 0.08, p = 0.003).
The association between BMD and CBFA1 and OCL expression
remained significant in a linear regression model adjusted for
gender, age, and BMI.
Additionally, we found that OCL gene expression level in the
plaques was higher in patients with dyslipidemia (1.12 ± 0.73
vs. 0.74 ± 0.69, p = 0.007). However, in multivariate analysis
OCL gene expression levels remained significantly associated
only with BMD.
The gene expression of inflammatory markers (IL-1β, IL-
6, IL-17A, and TNF) in the plaques was similar in patients
TABLE 1 | Clinical characteristics, co-morbidities and therapies of atherosclerosis






Age (years) 67.9 ± 8.6 73.0 ± 8.6 0.001
Gender 49 M/20 F 41 M/23 F 0.392
Alcohol (above 3U/day) 19 (27.5%) 15 (23.4%) 0.554
Calcium intake (mg/day) 848.6 ± 498.27 896.8 ± 468.9 0.372





Active lifestyle 7 (10.1%) 5 (7.8%) 0.724
BMI (Kg/m2) 28.5 ± 4.4 25.5 ± 4.0 <0.001
Hypertension 59 (85.5%) 49 (76.6%) 0.187
Previous CV event 44 (63.8%) 37 (57.8%) 0.482
Dyslipidemia 59 (85.5%) 53 (82.8%) 0.833
Type 2 Diabetes 20 (28.9%) 17 (26.6%) 0.716
Glucocorticoids (> 3 months) 4 (5.8%) 8 (12.5%) 0.167
Statins therapy 52 (75.4%) 46 (71.9%) 0.651
Quantitative variables are presented as means ± SD and qualitative variables as absolute
values and proportions of total (%). BMD, bone mineral density; BMI, body mass index;
CV, cardiovascular.
with normal and low BMD and was not related to other
patient’s characteristics (demographic, BMI, lifestyle habits, co-
morbidities or medication).
Histological Evaluation
Plaque CD3 and CD68 immunohistochemistry scores were
higher in patients with normal BMD than in patients with low
BMD (Table 3). Additionally, CD3 (0.82 ± 0.97 vs. 0.34 ± 0.53,
p = 0.006) and CD68 (0.89 ± 0.89 vs. 0.45 ± 0.63, p = 0.005)
immunohistochemistry scores were higher in male patients. In
the independent analysis, CD3 (ρ = −0.221, p = 0.009) and
CD68 (ρ = −0.181, p = 0.033) immunohistochemistry scores
were inversely related to patients age.
In a linear regression model adjusted for sex and age, CD68
scores were significantly associated with BMD (β = −0.203, p =
0.016). In a model with further adjustment to BMI, only gender
and BMI maintained a significant association with CD68 scores.
No significant correlations were found between any of the
histological studies performed (alizarin red S, CD3, CD68,
or adiponectin) and the results of the ELISAs or gene
expression quantifications.
Serum Cytokines and Bone Markers Analysis
Regarding serum levels analyzed, we did not find differences
between patients with normal or low BMD (Table 4).
No significant associations were found between gene
expression in the plaque and serum levels of bone remodeling
markers or inflammatory markers.
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TABLE 2 | Gene expression levels in the atheroma plaques of atherosclerosis






IL-1β 1.86 ± 1.57 1.59 ± 1.18 0.617
IL-6 0.65 ± 0.35 0.60 ± 0.31 0.527
IL-17A 1.62 ± 1.56 1.93 ± 1.95 0.360
TNF 137.2 ± 172.2 112.2 ± 175.6 0.262
RANKL 1.46 ± 0.95 1.23 ± 0.91 0.137
OPG 2.66 ± 1.99 2.29 ± 1.82 0.288
RANKL/OPG 0.46 ± 0.26 0.44 ± 0.28 0.767
COL1A1 0.89 ± 0.54 0.72 ± 0.48 0.065
CTSK 0.81 ± 0.49 0.77 ± 0.50 0.477
OCL 1.27 ± 0.84 0.84 ± 0.54 0.009
TRAP 6.93 ± 10.51 5.69 ± 7.54 0.442
CBFA1 0.98 ± 0.63 0.71 ± 0.47 0.015
DKK1 3.63 ± 2.67 3.04 ± 2.66 0.116
SOST 2.89 ± 1.89 2.89 ± 2.17 0.647
AdipoQ 34.4 ± 47.1 27.2 ± 35.6 0.671
AdipoR1 1.91 ± 1.16 1.62 ± 1.01 0.223
Variables are presented as means ± SD. BMD, bone mineral density; IL, Interleukin;
TNF, Tumor Necrosis Factor; RANKL, Receptor Activator of NF-kB Ligand; OPG,
Osteoprotegerin; COL1A1, Collagen type I; CTSK, Cathepsin K; OCL, Osteocalcin;
TRAP, Acid phosphatase tartrate resistant; CBFA1, Core-Binding Factor Alpha I; DKK1,
Dickkopf-related protein 1; SOST, Sclerostin; AdipoQ, Adiponectin; AdipoR1, Adiponectin
receptor 1.







Alizarin Red S 1.94 ± 0.95 1.92 ± 1.04 0.991
CD3+ 0.78 ± 0.91 0.47 ± 0.76 0.020
CD68+ 0.91 ± 0.84 0.55 ± 0.79 0.004
Adiponectin 1.16 ± 0.90 1.13 ± 0.90 0.780
Variables are presented as means ± SD. BMD, bone mineral density; CD, Cluster
of differentiation.
DISCUSSION
With our work we aimed to understand how atherosclerotic
lesions are related with disturbances in bone and specifically if
there is a role for inflammation in this relationship.
Regarding several genes related to inflammation and bone
remodeling we found that, at the gene expression level, there
was a positive correlation between bones and vessels, specifically
with the aorta, suggesting a link between these two systems.
In addition, the observed correlation did not extend to adipose
tissue, which supports that this is not a widespread finding.
No differences on the gene expression pattern with age
or sex were found in deceased donors’ samples, suggesting
that the relationships described above do not vary significantly
throughout life, neither between women and men, pointing
that, in pathologic processes, bone and vessel disturbances are






IL-1β (fg/mL) 14.8 ± 49.1 12.9 ± 35.8 0.780
IL-6 (fg/mL) 2139.5 ± 1730.7 1982.3 ± 1953.7 0.235
IL-17A (fg/mL) 17.9 ± 50.2 15.3 ± 30.8 0.380
TNF (fg/mL) 11.8 ± 47.7 8.02 ± 37.2 0.352
RANKL (pmol/L) 0.022 ± 0.019 0.019 ± 0.015 0.389
OPG (pmol/L) 8.11 ± 5.45 7.97 ± 5.44 0.885
RANKL/OPG 0.0033 ± 0.0040 0.0034 ± 0.0040 0.990
CTX (ng/mL) 30.8 ± 6.9 30.8 ± 8.3 0.865
P1NP (ng/mL) 130.5 ± 75.2 135.6 ± 75.4 0.678
CTX/P1NP 0.21 ± 0.09 0.23 ± 0.08 0.288
Adiponectin (ng/mL) 114909.4 ± 93591.1 130745.4 ± 99158.3 0.403
Variables are presented as means ± SD. BMD, bone mineral density; IL, Interleukin;
TNF, Tumor Necrosis Factor; RANKL, Receptor Activator of NF-kB Ligand; OPG,
Osteoprotegerin; CTX, C-terminal telopeptide of type 1 collagen; P1NP, procollagen type
1 N propeptide.
possibly linked due to an intrinsic connection between the tissues
involved. To the best of our knowledge there are no previous
reports of any relation between the expression of these genes,
either in the vessels or in bones, with age or gender.
We could not find an association between gene expression
and the circulating levels of the same proteins. As reviewed by
Vogel et al. (22) 60% of the variation in protein concentration
that cannot be explained by measuring mRNAs alone is at least
partially due to translation and protein degradation. Other works
have also observed the lack of association between OPG, PTH,
and RANKL gene expression in bone and serum levels (23, 24).
In the second part of our work we have used atherosclerotic
plaques from patients with advanced atherosclerosis that were
submitted to endarterectomy surgery and where bone mineral
density was evaluated by DXA. We found that more than 45%
of the enrolled patients had low BMD, which is in accordance
with the age range of this population and with previous studies
where bones and vessels were both evaluated by imagingmethods
(25, 26).
We found that the expression of bone formation genes
(CBFA1 and OCL) on atherosclerotic plaques was lower in those
patients who have decreased BMD. Yet, our results do not suggest
lower risk of plaque calcification, as we have not found any
differences in the calcium content between patients with normal
or low BMD.
The presence of these proteins in plaques is in accordance
with previous studies showing that calcified plaques composition
share some features of bone structure (27), but these results
seem contradictory to other studies (28–30) that reported an
association between low BMD and vascular calcification. These
differences might be related to different methodologies used to
quantify vascular calcification (microscopic vs. macroscopic) and
also to different stages of plaque development, as calcification can
begin at any point of plaque formation and progression (27).
When analyzing the results of immunohistochemical
staining performed on the atherosclerotic plaques, our results
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support that atheroma plaques from men have higher levels
of inflammation, as previously proposed (31, 32). BMI
also influences plaques inflammatory score, highlighting
the link between obesity and atherosclerosis progression
(33). Accordingly, in deceased donors, serum levels of
pro-inflammatory cytokine IL-1β were also higher in men.
Patients with low BMD had plaques with lower inflammatory
profile. Low BMD has been associated with echogenic (more
calcified) plaques (34, 35) and calcification and inflammation are
thought to be active at different stages of disease progression
(36), with inflammation at early phases and calcification
predominantly later (32, 37), which might explain our findings.
Despite the limitations related to the cross-sectional design,
correlative nature of the work with lack of functional data,
and the lack of clinical information of deceased donors, our
study has some strengths. Samples from deceased donors allowed
us to directly evaluate gene expression on bone and aortas
from the same subjects and in a wide range of ages, going
behind indirect diagnostic methods used in vivo. Regarding
atherosclerosis patients, we did not have access to bone tissue
of these patients to perform the study directly on the affected
tissue. However, contrary to most studies, we had access to
carotid atheroma plaques, and not only to ultrasound evaluation
of atherosclerosis, and all patients had BMD evaluated by DXA.
CONCLUSIONS
We have described a positive correlation between bone and aorta
concerning the expression of inflammation and bone remodeling
genes, independent of age and sex. Bone-remodeling genes are
not only expressed on atherosclerotic plaques, but also on vessel
walls, regardless of the presence of plaques.
Additionally, the atheroma plaques of patients with low BMD
present lower levels of bone formation markers (CBFA1 and
OCL) and a lower score CD68 immunostaining than those with
normal BMD.
Our results suggest that the relationship between the changes
observed in vessels and bones in the context of atherosclerotic
disease and OP may rely on the intrinsic connection between the
tissues involved, independently of the disease stage.
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